Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305799 · ClinicalTrials.gov registry record
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 59
- Enrollment target
NCT00305799: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT00305799 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305799 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tumors. PURPOSE: This clinical trial is studying hearing loss and dizziness in patients receiving oxaliplatin for solid tumors.
Interventions
- PROCEDURE management of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-11 |
| Est. Completion | 2014-11 |
What the finished NCT00305799 record still lists
NCT00305799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which management of therapy complications is the first listed.
NCT00305799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00305799 about?
NCT00305799 is a clinical study titled "Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors". RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tumors. PURPOSE: This clinical trial is studying hearing loss and dizziness in patients receiving oxal...
What is the current status of trial NCT00305799?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2005-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00305799?
The interventions under investigation include: management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00305799?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia